Longevity Treatments: What Works, What Is Promising and What Is Hype

When people ask for the best longevity treatment, they often picture a new molecule, an infusion or an impressive-looking chamber. The real answer rarely fits a catalogue. It depends on the risk you carry, the outcome you want to change and how much uncertainty you are prepared to accept.

One truth belongs at the top: no drug, device or infusion has been shown to broadly slow or reverse human aging. FDA maintains the same warning. We do know how to reduce heart attacks, strokes, fractures, disability, muscle loss and some preventable cancers. That is also healthspan medicine, even when it does not look futuristic.

This map does not rank treatments by novelty. It ranks them by what they have demonstrated in people.

Start by separating two questions

Question one: what lowers my risk of disease or functional loss? Exercise, food, sleep, vaccines, screening and treatment of blood pressure, lipids, glucose, obesity, osteoporosis or defined symptoms belong here.

Question two: what directly modifies the biology of aging and makes a healthy person live longer and better? Metformin, rapamycin, NAD+, senolytics and other geroscience strategies aim at this question, but none has provided a general clinical demonstration.

Mixing the two questions lets an experimental intervention borrow the credibility of prevention that already works.

Four levels that should not share one label

Level	Examples	What we can say
Clinical foundation	Movement, strength, food, sleep, no smoking, less alcohol, indicated vaccines and screening.	Reduces disease or disability in defined populations. This is the highest-yield foundation.
Indicated treatment	Antihypertensives, statins, GLP-1 drugs, menopausal hormone therapy or osteoporosis medicines.	Can improve specific outcomes when expected benefit exceeds harm. It is not universal anti-aging.
Promising or investigational	Geroprotective rapamycin, metformin in healthy adults, NAD+, senolytics, plasma exchange or selected hyperbaric protocols.	A mechanism, biomarker or early signal may exist. Evidence for healthspan, long-term safety or mortality is missing.
Unproven and higher risk	Unapproved peptides, secret blends, RUO vials and products with uncertain identity or sterility.	Benefit cannot be promised, and product quality may add harm unrelated to the proposed mechanism.

What does it really mean for something to “work”?

Better glucose, more NAD+, longer telomeres or a younger epigenetic age can be interesting. They are not automatically better mobility, fewer heart attacks or a longer life. A convincing treatment should define:

• who receives it and their starting risk;
• product, dose, route and duration;
• comparator and meaningful endpoint;
• absolute benefit, not only a relative percentage;
• adverse effects, withdrawals and follow-up;
• what decision changes after a positive or negative result.

Our guide to longevity biomarkers explains why one clock cannot carry that whole burden of proof.

The strongest healthspan tools do not look like science fiction

Movement, strength and function

WHO recommends 150 to 300 minutes of moderate aerobic activity each week for adults, or 75 to 150 minutes vigorous, plus muscle strengthening on at least two days. Not everyone begins at that dose. Pain, frailty, heart disease and experience change the progression.

The LIFE trial gives us a concrete picture. It included 1,635 sedentary adults aged 70 to 89 with functional limitations. After an average 2.6 years, major mobility disability occurred in 30.1% of the structured-activity group and 35.5% of the health-education group. That is a 5.4-point absolute difference, not a promise of immortality.

Walking, cycling, pushing, pulling, standing up and practising balance can seem modest. Their advantage is that they change capacity and independence, outcomes that matter outside the laboratory.

Sustainable food and usable muscle

PREDIMED enrolled 7,447 Spanish adults at high cardiovascular risk. Participants followed a Mediterranean diet supplemented with extra-virgin olive oil or nuts, or a control diet. Cardiovascular events were less frequent in both Mediterranean groups. The paper was republished after randomisation deviations were identified, a detail that also belongs in an honest reading.

The priority is not finding a rejuvenating food. It is building a pattern around vegetables, whole fruit, legumes, nuts, olive oil, fish and minimally processed food, then protecting muscle through resistance training and adequate intake. Our guide to sarcopenia and muscle loss turns that into strength, function and follow-up.

Smoking, alcohol and sleep

Stopping smoking remains one of the highest-impact decisions for vascular, lung, cancer and mortality risk. With alcohol, less exposure reduces risk; there is no reason to start drinking for longevity. With sleep, adding time in bed does not by itself treat sleep apnoea, chronic insomnia, restless legs or depression. Find the bottleneck first.

Treating a real risk is not rejuvenation, but it changes the future

Blood pressure and cholesterol illustrate the distinction. SPRINT enrolled 9,361 adults at high cardiovascular risk without diabetes or previous stroke and assigned two systolic blood-pressure targets. Intensive treatment reduced the main cardiovascular outcome from 2.40% to 1.77% per year while increasing hypotension, electrolyte abnormalities and acute kidney injury. This is not a target to copy at home. It is an example of benefit and harm measured in the right population.

In a meta-analysis of 27 trials and about 174,000 people, each 1 mmol/L reduction in LDL with statins was associated with 21% fewer major vascular events in relative terms. Absolute benefit rises with baseline risk. A statin does not rejuvenate a cell, but it can prevent some vascular disease.

The same logic applies to diabetes, bone health, vaccines and screening: indication, risk, preference and follow-up. More treatment does not always mean more health.

Powerful medicines with a defined indication

GLP-1 drugs: cardiometabolic benefit, not proof of anti-aging

SELECT included 17,604 adults with overweight or obesity, established cardiovascular disease and no diabetes. With semaglutide 2.4 mg weekly, the cardiovascular composite occurred in 6.5%, compared with 8.0% on placebo. That is a 1.5-point absolute reduction in this population.

The result matters. It does not show that semaglutide slows aging in a healthy person. Nausea, vomiting, gallbladder disease, dehydration, lean-mass loss, contraindications, cost and maintenance belong in the decision.

Menopausal hormone therapy

Hormone therapy is the most effective treatment for vasomotor symptoms and prevents bone loss while used. In women younger than 60 or within ten years of menopause onset, without contraindications, the benefit-risk balance is often favourable for troublesome symptoms and bone protection.

It is not prescribed to stop aging. Hormone type, route, uterus, migraine, thrombosis, bleeding, cancer and cardiovascular risk change the conversation. Periodic reassessment is part of treatment.

What should we do with promising therapies?

Intervention	What is interesting	What is missing before we call it longevity treatment
Metformin and rapamycin	Metformin has metabolic uses; rapamycin extends life in several models and is being studied in humans.	Net clinical benefit and long-term safety in healthy adults. Rapamycin remains an immunosuppressant with interactions and adverse effects.
NAD+, NR and NMN	NR and NMN raise NAD-related metabolites in human studies.	Consistent functional outcomes and outcome trials. A 2026 review found no eligible IV NAD+ trial with clinical anti-aging outcomes.
Senolytics	Removing senescent cells is a strong hypothesis, and early human disease-specific trials exist.	A defined product, dose and population with reproducible clinical improvement and acceptable toxicity.
Plasma exchange and hyperbaric oxygen	They have specific medical indications and biomarker signals in experimental settings.	Controlled trials in the target population with function, disease or survival, not laboratory changes alone.
Peptides and RUO vials	Some animal mechanisms justify research.	Pharmaceutical identity, human exposure, efficacy and safety. FDA continues to flag major gaps for BPC-157, MOTS-C and TB-500.

“Investigational” does not mean “it will never work”. It means we do not yet know whether benefit exceeds risk. That sentence protects scientific curiosity and the person who must decide today.

A simple method before you pay

1. Define the outcome. Translate “feel younger” into pain, fatigue, sleep, strength, aerobic capacity, weight, glucose or a clinical event.
2. Check the population. A trial in diabetes, Alzheimer’s disease or wound care does not establish benefit in a healthy person.
3. Ask for the real product. Name, manufacturer, concentration, route, sterility and regulatory status should be transparent.
4. Quantify benefit and harm. Ask how many improved, how many stopped and how long follow-up lasted.
5. Compare alternatives. A new intervention competes with treating blood pressure, apnoea, muscle loss or overdue screening.
6. Set a stopping rule. Review or stop if the agreed metric does not improve or harm appears.

A serious clinic should answer without turning each question into another sale. Our guide to choosing a longevity clinic brings together ten practical criteria.

Do not relabel a warning sign as “aging”

Chest pain, new shortness of breath, fainting, one-sided weakness, speech difficulty, sudden severe headache, unexplained bleeding, persistent fever, unintentional weight loss, a new mass or rapid cognitive change require prompt medical assessment. So does a severe reaction after an injectable, or fever and significant pain after an infusion. A longevity programme must never delay emergency care or conventional diagnosis.

Frequently asked questions

Has any treatment been proven to slow human aging?

No. No drug, infusion or device has been shown to broadly slow or reverse human aging and extend healthy lifespan. Prevention and indicated treatment can still reduce disease, events and functional loss.

Which longevity treatments have the strongest evidence?

Those that address a real risk: smoking cessation, aerobic and resistance exercise, high-quality food, adequate sleep, indicated vaccines and screening, and treatment of hypertension, high LDL, diabetes, obesity or osteoporosis when appropriate.

Are GLP-1 drugs anti-aging treatments?

No. They treat diabetes or obesity in defined populations. Semaglutide reduced cardiovascular events in people with overweight or obesity and established cardiovascular disease, but that does not show a general slowing of aging.

Should a healthy person take metformin or rapamycin?

Current evidence does not support routine use for longevity in healthy adults. Metformin has metabolic indications and rapamycin is an immunosuppressant; possible geroprotection remains under investigation.

What do we know about NAD+ and other experimental therapies?

In humans, NR and NMN raise NAD-related metabolites, but functional results are mixed and no outcome trial validates intravenous NAD+ for wellness. A biomarker or small signal does not demonstrate a longer healthy life.

Does a lower biological age prove that a treatment works?

No. It may be an exploratory signal, but we need reproducibility, a comparator, sufficient follow-up and a link to function, disease, disability or survival before changing practice.

What are the signs that a longevity clinic is selling hype?

Rejuvenation promises, testimonials as proof, injectables with unclear status, hidden risks or origin, dependence on one aging clock, and packages sold before defining an outcome, alternative and stopping rule.

How do I choose my first longevity priority?

Start with the modifiable risk most likely to matter for you. It may be smoking, blood pressure, LDL, glucose, muscle loss, sleep, bone health or overdue screening. Your baseline sets the priority, not the newest treatment.

Sources reviewed

1. FDA, medication health fraud for anti-aging products: no medication has been proven to slow or reverse aging.
2. WHO, physical activity and sedentary behaviour guideline: recommendations for adults and older adults.
3. LIFE trial: structured activity and mobility disability in older adults.
4. PREDIMED republication: Mediterranean patterns and cardiovascular events in high-risk adults.
5. SPRINT final report: benefits and harms of intensive blood-pressure control in a defined population.
6. CTT Collaboration: LDL reduction with statins and vascular events.
7. SELECT: semaglutide and cardiovascular outcomes in obesity without diabetes.
8. NAMS hormone therapy position statement: indication, timing and benefit-risk balance.
9. 2026 rapamycin review: human translation, trials and limitations.
10. 2026 NAD+ systematic review: biochemical target engagement and mixed functional outcomes.
11. FDA, bulk substances for compounding that may present significant risks: BPC-157, MOTS-C and TB-500.

The conclusion fits in one sentence: reduce the risk you can already measure first; if you explore after that, use a clear question, a known product and an exit rule. Novelty can wait. Your safety cannot.